PFE - Vaxart: Differentiated Covid Oral Route Remains Viable

• In an environment where injection-type vaccines are proving to offer somewhat reduced protection against the delta variant, the risks of being infected and transmitting the virus to others remain high.
• In this case, Vaxart's oral tablet vaccine, not to be confused with the antiviral pills being produced by Merck and Pfizer, does make a lot of sense for preventive purposes.
• This differentiation seems to have been ignored by the market, with Vaxart's shares trending lower.
• Considering potential sales of $1 billion, a target share price of $15 remains a moderate one, but it is better to remain prudent with the road leading to Phase 3 trials likely to be a long one.
• The implications of Vaxart's development could have a significant effect on Covid-19 progress, namely by encouraging a lot of people like myself to be orally inoculated instead of being jabbed again and again.

For further details see: